In Germany, the Association of Research-based Pharmaceutical Companies (VFA) and the Federation of the Pharmaceutical Industry (BPI) have welcomed the news that the Federal Ministry of Health has decided to continue its funding of the National Action Alliance for People with Rare Diseases (NAMSE).
Positive MAP InsightsNAMSE works to improve diagnosis of rare diseases and the care available for them, so its work is considered vital by patients living with their burden. NAMSE is made up of 25 bodies from healthcare, politics, science and other fields: a remarkable collaboration working towards its goals.
According to the press release from the BPI,
“The Association of Research-based Pharmaceutical Companies (vfa) and the Federation of the Pharmaceutical Industry (BPI) very much welcome the fact that thanks to funding from the Ministry, the work of NAMSE can now be continued. For patients with rare diseases, it is very important, because it is about the improvement of the diagnostic and care services.”
Read more here.